DeepMed Research

TEHRAN UNIVERSITY OF MEDICAL SCIENCES

🇮🇷Iran

Country: 🇮🇷Iran

Ownership: Private

Established: 1934-01-01

Employees: 1K

Market Cap: -

Website: http://www.tums.ac.ir

Clinical Trials

Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis

Phase 3

Completed

Conditions: Autoimmune Hepatitis

Interventions: Drug: Cyclosporine-A

First Posted Date: 2010-07-27

Last Posted Date: 2019-07-19

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 55

Registration Number: NCT01170351

Locations: 🇮🇷
Digestive Disease Research Center, Shariati Hospital, Tehran, Iran, Islamic Republic of

Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting

Not Applicable

Completed

Conditions: Cholangitis

Interventions: Drug: gentamicin
Drug: Placebo

First Posted Date: 2010-06-22

Last Posted Date: 2011-09-20

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 114

Registration Number: NCT01148693

Locations: 🇮🇷
TUMS Digestive Disease Research Center, Tehran, Iran, Islamic Republic of

Pegaferon and Ribavirin for Hepatitis C

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Pegaferon (pegylated interferon alpha 2a) + ribavirin

First Posted Date: 2010-06-04

Last Posted Date: 2010-06-30

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 108

Registration Number: NCT01137383

Locations: 🇮🇷
Emam Hospital, Tehran, Iran, Islamic Republic of
🇮🇷
Shariati Hospital, Tehran, Iran, Islamic Republic of

Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Pioglitazone+Citalopram+Chlordiazepoxide
Drug: Placebo+ Citalopram+ Chlordiazepoxide

First Posted Date: 2010-04-22

Last Posted Date: 2012-05-09

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT01109030

Locations: 🇮🇷
Department of psychiatry, Roozbeh psychiatric hospital, Tehran University of medical sciences, Tehran, Iran, Islamic Republic of

Sildenafil and Uteroplacental Perfusion

Phase 2

Conditions: Fetal Growth Retardation

Interventions: Drug: sildenafil
Drug: placebo

First Posted Date: 2010-04-21

Last Posted Date: 2011-02-23

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 70

Registration Number: NCT01107782

Locations: 🇮🇷
Tehran UMS, Tehran, Iran, Islamic Republic of

Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder

Phase 2

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: methylphenidate+carnitine
Drug: Methylphenidate+placebo

First Posted Date: 2010-04-06

Last Posted Date: 2012-12-07

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01099072

Locations: 🇮🇷
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Amantadine
Drug: ritalin

First Posted Date: 2010-04-06

Last Posted Date: 2010-11-18

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01099059

Locations: 🇮🇷
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

Phase 2

Conditions: Osteopetrosis

Interventions: Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
Procedure: Stem Cell Transplantation
Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)

First Posted Date: 2010-03-16

Last Posted Date: 2012-06-04

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 10

Registration Number: NCT01087398

Locations: 🇮🇷
Hematology-Oncology & SCT Research Center, Tehran, Iran, Islamic Republic of

The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery

Phase 1

Completed

Conditions: Hemorrhage

Interventions: Drug: Normal saline
Drug: Tranexamic acid

First Posted Date: 2010-03-11

Last Posted Date: 2011-01-25

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT01085006

Locations: 🇮🇷
Laleh Eslamian, Tehran, Iran, Islamic Republic of

Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis

Early Phase 1

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Liposomal meglumine antimoniate
Drug: Liposomal meglumine antimoniate (Glucantime)
Drug: Liposomal Paromomycin
Drug: Placebo

First Posted Date: 2010-01-15

Last Posted Date: 2012-06-20

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT01050777

Locations: 🇮🇷
Emam Reza Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy